PTC Therapeutics announced the appointment of Pierre Gravier to the role of CFO. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, an independent global advisory firm.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PTCT:
- Investors had ‘modest expectations’ for PTC’s vatiquinone, says Morgan Stanley
- Cantor trims PTC Therapeutics target to $73, says vatiquinone not core to story
- PTC study failure has minimal impact on thesis, says William Blair
- PTC Therapeutics’ vatiquinone did not meet primary endpoint in MDAS study
- PTC Therapeutics management to meet with Truist